Table 1

Clinicopathologic characteristics of patients in the two cohorts*

CharacteristicNode negative cohort
(n=452)
SLN–ITC cohort
(n=42)
P value†
Year of surgery<0.01
 2012–1444 (9.7)2 (4.8)
 2015–17308 (68.1)12 (28.6)
 2018–19100 (22.1)28 (66.7)
Age at surgery (years) (mean (SD))62.5 (9.7)60.8 (10.6)0.29
Body mass index (kg/m2) (mean (SD))35.3 (8.4)34.7 (9.7)0.69
Tumor diameter (mm) (median (IQR))32 (21, 43)34 (25, 43)0.62
Grade0.26
 1347 (76.8)29 (69.0)
 2105 (23.2)13 (31.0)
LVSI<0.01
 No445 (98.5)35 (83.3)
 Yes7 (1.5)7 (16.7)
Myometrial invasion0.86
 None124 (27.4)11 (26.2)
 <50%328 (72.6)31 (73.8)
Peritoneal cytology0.20
 Negative353 (78.1)28 (66.7)
 Positive29 (6.4)5 (11.9)
 Not sampled70 (15.5)9 (21.4)
  • Values are number (%) unless otherwise indicated.

  • *All patients considered FIGO stage IA.

  • †Comparisons between groups were evaluated using the two sample t test for age and body mass index, Wilcoxon two sample test for tumor diameter, and the χ2 or Fisher’s exact test for each of the categorical variables.

  • FIGO, International Federation of Gynecology and Obstetrics; ITC, isolated tumor cell; LVSI, lymphovascular space invasion.